truth, page-14

Axiron is definitely a trooper - remarkable really. Only a 5% dip is really good and at that rate of decrease in sales it will have a long tail - we should be able to fund the new products despite the high cost and long time frame. Just as well - if they expect us holders to pony up more money then they should forget it.

Your point about the generics is the kicker. If some clever person is able to come up with figures re market penetration of the competition then we will really know where we are with revenues moving forward. Good point.

I am still convinced that any re-start of divies is unlikely. Considering their behavior they probably know that their holders hate them to the point where they are ready to see their investment go to zero rather than give them another red cent. (Well at least this investor does) However, given Axiron holds up just maybe it might happen.